Aeglea BioTherapeutics Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Aeglea BioTherapeutics

Access the complete profile.

Aeglea BioTherapeutics Fast Facts

Revenue	$10 - $100 million    See Exact Annual Revenue
Employees	10 - 100Exact Company Size
Primary Industry	622 Hospitals
Address	805 Las Cimas Parkway Suite 100 Austin, TX 78746

Note: Revenues for privately held companies are statistical evaluations.


Aeglea BioTherapeutics's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Aeglea BioTherapeutics's annual revenues are $10 - $100 million (see exact revenue data)
• What industry is the company in?
  • Aeglea BioTherapeutics is classified as operating in the Hospitals industry, NAICS Code 622.

Aeglea BioTherapeutics Annual Revenue and Growth Rate

Aeglea BioTherapeutics	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2025	$10 - $100 million Details in Premium Report
2024
2023
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Aeglea BioTherapeutics's revenues are gauged from an analysis of company filings.

Aeglea BioTherapeutics's Income Statement (based on Industry Averages)

Aeglea BioTherapeutics P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Aeglea BioTherapeutics is developing and marketing. Aeglea BioTherapeutics doesn't have any recent trademark applications, indicating Aeglea BioTherapeutics is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
AEGLEA Pharmaceutical preparations for the treatment of rare genetic diseases; pharmaceutical preparations for the treatment of Arginase 1 deficiency; pharmaceutical preparations for the treatment of cancer; biopharmaceutical preparations for the treatment of rare genetic diseases; biopharmaceutical preparations for the treatment of Arginase 1 deficiency; biopharmaceutical preparations for the treatment of cancer; biotherapeutic preparations for the treatment of rare genetic diseases; biotherapeutic preparations for the treatment of Arginase 1 deficiency; biotherapeutic preparations for the treatment of cancer; biotherapeutic preparations and substances for the treatment of rare genetic diseases; biotherapeutic preparations and substances for the treatment of Arginase 1 deficiency; biotherapeutic preparations and substances for the treatment of cancer; enzyme replacement therapy preparations for medical purposes; pharmaceutical preparations for the prevention and treatment of infectious diseases and immunological diseases; biopharmaceutical preparations for the prevention and treatment of infectious diseases and immunological diseases; pharmaceutical preparations for the treatment of homocystinuria; biopharmaceutical preparations for the treatment of homocystinuria; biotherapeutic preparations for the treatment of homocystinuria	08/26/2020
LOARGYS Pharmaceutical preparations for the treatment of rare genetic diseases; pharmaceutical preparations for the treatment of Arginase 1 deficiency; pharmaceutical preparations for the treatment of cancer; biopharmaceutical preparations for the treatment of rare genetic diseases; biopharmaceutical preparations for the treatment of Arginase 1 deficiency; biopharmaceutical preparations for the treatment of cancer; biotherapeutic preparations for the treatment of rare genetic diseases; biotherapeutic preparations for the treatment of Arginase 1 deficiency; biotherapeutic preparations for the treatment of cancer; biotherapeutic preparations and substances for the treatment of rare genetic diseases; biotherapeutic preparations and substances for the treatment of Arginase 1 deficiency; biotherapeutic preparations and substances for the treatment of cancer; enzyme replacement therapy preparations for medical purposes	09/23/2019
ZARNUMI Pharmaceutical preparations for the treatment of rare genetic diseases; pharmaceutical preparations for the treatment of Arginase 1 deficiency; pharmaceutical preparations for the treatment of cancer; biopharmaceutical preparations for the treatment of rare genetic diseases; biopharmaceutical preparations for the treatment of Arginase 1 deficiency; biopharmaceutical preparations for the treatment of cancer; biotherapeutic preparations for the treatment of rare genetic diseases; biotherapeutic preparations for the treatment of Arginase 1 deficiency; biotherapeutic preparations for the treatment of cancer; biotherapeutic preparations and substances for the treatment of rare genetic diseases; biotherapeutic preparations and substances for the treatment of Arginase 1 deficiency; biotherapeutic preparations and substances for the treatment of cancer; enzyme replacement therapy preparations for medical purposes	09/23/2019

See all trademarks and details in the Full Report.

Market Share of Aeglea BioTherapeutics's Largest Competitors

A competitive analysis shows these companies are in the same general field as Aeglea BioTherapeutics, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
TRINITY HEALTH	Livonia, MI	100
1199SEIU NATIONAL BENEFIT FUND FOR HEALTH & HUMAN SERVICE EMPLOYEES	New York, NY	74
TENET HEALTHCARE	Dallas, TX	69
UPMC	Pittsburgh, PA	63
COMMONSPIRIT HEALTH	Erlanger, KY	58
NJHA INSURANCE FUND	Princeton, NJ	58
PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA	Renton, WA	54
ADVOCATE AURORA HEALTH	Downers Grove, IL	53
CLEVELAND CLINIC FOUNDATION	Cleveland, OH	46

Nearby Competitors

These companies are similar in business line and location to Aeglea BioTherapeutics. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
WESTLAKE SURGICAL	West Lake Hills, TX	100
CROCKETT MEDICAL CENTER	Austin, TX	50
ST. DAVID'S FOUNDATION	Austin, TX	42
CENTRAL TEXAS MEDICAL SPECIALISTS PLLC	Austin, TX	24
AEGLEA BIOTHERAPEUTICS	Austin, TX	21
LAKE TRAVIS ER LLC.	Austin, TX	13

Future Competition: Aeglea BioTherapeutics's Fastest Growing Competitors

These companies are in the same general field as Aeglea BioTherapeutics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)